Ideas catalog
Every idea we've derived from recent research — each with a live, interactive prototype you can try.
A viable, evidence-backed simulation tool for urban planners, though it faces significant competition from established GIS and traffic modeling incumbents.
Backed by 2 papers
A niche B2B certification service targeting the shift toward 3D-printed aligners by quantifying material degradation and chemical leaching, though it faces a steep climb to become a recognized industry standard.
Backed by 3 papers
A high-potential therapeutic probiotic with a strong biological mechanism, though it faces significant regulatory hurdles as a medical-grade intervention for kidney injury.
A high-risk, high-reward drug discovery play targeting a specific receptor location to decouple therapeutic neuroplasticity from hallucinogenic effects.
A promising, biologically grounded probiotic with a clear clinical wedge, though it faces significant regulatory hurdles regarding live bacterial colonization in high-risk patients.
A high-potential clinical intervention targeting a specific surgical complication with strong mechanistic backing, though it faces significant regulatory hurdles.
A niche B2B tool with strong academic backing but limited market viability due to the extreme dependency on slow-moving public infrastructure deployment.
Backed by 2 papers
A highly specific diagnostic tool for a rare genetic cause of male infertility, though its commercial viability is limited by the low prevalence of the target mutation.
Backed by 2 papers
A pragmatic utility tool that solves a known friction point in computational chemistry, though it risks being a feature rather than a standalone company.
A clinically well-grounded AUD treatment concept with a specific RCT-validated protocol and real market need, but near-term commercial viability is severely constrained by federal Schedule I status and an immature regulatory framework.
Backed by 4 papers
A high-risk, high-reward tool that attempts to turn eye-tracking into a compliance audit trail, though it faces significant hardware and psychological hurdles.
Backed by 5 papers
A niche tool for a highly specialized academic market that likely lacks the budget or incentive to purchase proprietary software over open-source community scripts.
A focused materials-safety certification service for dental aligners that fills a genuine regulatory gap, but rests on a single study and faces an unproven willingness-to-pay model.
Backed by 2 papers
A focused data-intelligence layer turning a credible material-flow analysis into actionable refrigerant-recovery targeting for carbon credit developers, with a real but modeling-dependent wedge.
A high-potential clinical tool that is currently undermined by a critical mismatch between the theoretical mathematical model provided and the practical biological data required for implementation.
Mechanistically sharp companion diagnostic concept riding the GLP-1RA wave, but the commercial thesis rests almost entirely on mouse knockout data with only indirect human metabolite evidence, leaving a large clinical-validation gap before any CDx submission is conceivable.
Backed by 2 papers
A high-friction hardware retrofit that addresses a looming regulatory cliff (EURO 7), though it faces significant engineering hurdles regarding vehicle aerodynamics and maintenance.
Backed by 3 papers
A focused, clinically validated AI plug-in for standardizing midpalatal suture maturation scoring—a real diagnostic pain point—but it solves a narrow sub-problem that fits better as a feature inside larger imaging platforms than as a standalone venture.
Backed by 2 papers
A clinically grounded orthodontic outcomes registry with a real niche, but it faces hard data-aggregation hurdles and an uncertain willingness-to-pay in a relatively narrow vertical.
Backed by 3 papers
Compelling clinical evidence and a clear unmet need are fatally undermined by the FDA's August 2024 Complete Response Letter rejecting Lykos's NDA, which renders the 'why now' premise commercially inert for the foreseeable future.